In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target of $70.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Rami Katkhuda has given his Buy rating due to a combination of factors including Vera Therapeutics’ strong financial position and promising clinical developments. The company concluded Q1 2025 with a substantial cash reserve of $589.8 million, which is anticipated to sufficiently support operations through the potential approval and commercial launch of atacicept for IgA nephropathy (IgAN).
Furthermore, Vera Therapeutics is on track to release topline results from its Phase III ORIGIN 3 study in Q2 2025. The expected outcomes, such as a significant placebo-adjusted proteinuria reduction, could pave the way for a Biologics License Application (BLA) submission by the end of 2025. Additionally, the long-term efficacy and safety data of atacicept, including eGFR stabilization, position it as a potentially groundbreaking treatment in its class, enhancing its competitive edge against rivals like Otsuka’s sibeprenlimab.
In another report released yesterday, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $75.00 price target.